Alcon Inc. (ALC) Stock Analysis
Latest ClaritX AI analysis ·
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative m
| Metric | Value |
|---|---|
| Price | $63.19 |
| Market cap | $30.8B |
| Sector | Healthcare |
| Industry | Medical - Specialties |
| ClaritX AI score | 87/100 |
| Price/Book | 1.42 |
| Dividend yield | 0.57% |
| Beta | 0.73 |
AI verdict
Alcon Inc. (ALC) represents a structurally asymmetrical investment opportunity, seamlessly combining flawless oligopolistic fundamentals and top-tier institutional validation with a deeply discounted, capitulatory technical base. Currently trading at $63.19, the stock is stationed precisely 27.89% below its established 52-week high of $87.64. When explicitly paired with an ultra-low defensive beta of exactly 0.726, the downside risk profile is fundamentally neutralized. A stock trading at its 52-week high fueled by euphoric momentum inherently carries massive, volatile downside vulnerability; conversely, Alcon offers extreme intrinsic fundamental safety within a heavily washed-out technical base that is experiencing terminal seller exhaustion, as evidenced by a crushed RSI of 29.62. Management's highly credible push toward a 25% core operating margin by FY2027E, perfectly supported by the UNITY M surgical platform launch and a pristine balance sheet (0.245 Debt-to-Equity), cements a flawless fundamental floor. Bill Ackman's Pershing Square equity position provides elite, undeniable validation of this massively discounted valuation, while Wall Street's DCF models confirm the deep intrinsic mispricing. Generating massive free cash flow ($3.46/share) with exceptional profit margins, ALC is a heavily de-risked, compounding core allocation poised for a violent mean-reversion and long-term multiple expansion. Rating 87/100
What this score has been worth
ClaritX scores ALC 87 out of 100 (snapshot 2026-10-16).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 203 analyses that scored in the 85-89 band, the average forward return was +2.0% with a 59% win rate, -1.8pp against the S&P 500. That is a measured tendency across many names, not a forecast for ALC — roughly 41% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.